A Phase 3 interventional study of Teduglutide and Syringe in Short Bowel Syndrome, sponsored by Takeda. Completed at 5 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-03-15.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 13th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 16th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2018.
This study's enrollment of 11 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2018, is one of 17 in phase 3, and was the 16th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate the long-term safety and efficacy of teduglutide in Japanese participants with PN/IV (parenteral nutrition/intravenous)-dependent SBS (short bowel syndrome) who completed SHP633-306 or who were in the extension phase of the TED-C14-004 (NCT02340819) study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who meet all of the following criteria will be enrolled in this study:
Exclusion Criteria:
There are no exclusion criteria for this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm until Teduglutide is commercially available, the participant's participation in this study is discontinued, or the study is discontinued.
Drug: Teduglutide · Device: Syringe · Device: Needle · Device: Vial Adapter for Device
Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
Vial adapter for device is approved for use in Japan by PMDA.
Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Change From Baseline in Weekly PS Volume
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Percent Change From Baseline in Weekly PS Volume
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS)
Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Change From Baseline in Days Per Week of PS
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Change From Baseline in Plasma Citrulline Levels
Plasma citrulline was measured as an assessment of enterocyte mass. Plasma samples were analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants With Clinically Significant Change From Baseline in Laboratory Values
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS
Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Change From Baseline in 48-Hour Urine Output
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants With Clinically Significant Change From Baseline in BMI
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
Time frame: Baseline (core study) up to approximately 40.2 months (duration of assessment in the current study)
Number of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results
Time frame: From the first dose of study drug (in current study) up to EOS (up to approximately 42 months)
Participants took part in the study at 5 investigative sites in Japan from 09 July 2018 to 13 January 2022.
| Milestone | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg |
|---|---|---|
| Started | 4 | 7 |
| Completed | 3 | 6 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 1 | 0 |
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg |
|---|---|---|
| Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume | 3 | 5 |
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| liter per week (L/Week) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg |
|---|---|---|
| Change From Baseline in Weekly PS Volume | -7.45 ± 7.908 | -8.67 ± 7.450 |
The weekly volume was calculated as (sum of daily volumes in the diary/number of days with values)\*7. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| percent change | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg |
|---|---|---|
| Percent Change From Baseline in Weekly PS Volume | -49.55 ± 41.411 | -52.52 ± 39.828 |
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg |
|---|---|---|
| Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS) | 1 | 2 |
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| days per week | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg |
|---|---|---|
| Change From Baseline in Days Per Week of PS | -2.3 ± 3.30 | -2.0 ± 3.42 |
Plasma citrulline was measured as an assessment of enterocyte mass. Plasma samples were analyzed using a validated high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| micromoles per liter | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg |
|---|---|---|
| Change From Baseline in Plasma Citrulline Levels | 12.96 ± 5.568 | 19.15 ± 18.851 |
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| TEAE | 4 | 7 | 11 |
| TESAE | 3 | 4 | 7 |
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Values | 0 | 0 | 0 |
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Sign Measurements | 0 | 0 | 0 |
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Values | 0 | 0 | 0 |
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Number of Participants Who Reported Positive Specific Antibodies to Teduglutide at EOS | 3 | 4 | 7 |
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| Milliliter per day (mL/day) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Change From Baseline in 48-Hour Urine Output | 428.8 ± 286.57 | 308.6 ± 589.36 | 352.3 ± 486.54 |
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Body Weight Measurements | 0 | 0 | 0 |
Baseline data refer to the baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]), however the time frame represents the duration for which participants were assessed in current study. The only data presented from the Core Studies in this report are the comparison of the Extension Study data with the Baseline data of the Core Study.
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in BMI | 0 | 0 | 0 |
| Participants | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Number of Participants With Clinically Significant Colonoscopy/Sigmoidoscopy Results | 0 | 0 | 0 |
Collected over TEAEs were defined as AEs that started on or after the first dose of study drug (in current study) up to approximately 42 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SHP633-306: Teduglutide 0.05 mg/kg | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| TED-C14-004: Teduglutide 0.05 mg/kg | 0/7 (0%) | 4/7 (57.1%) | 7/7 (100%) |
| Total Participants | 1/11 (9.1%) | 7/11 (63.6%) | 11/11 (100%) |
| Event | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| Device related infectionInfections and infestations | 0/4 | 4/7 | 4/11 |
| CholecystitisHepatobiliary disorders | 1/4 | 0/7 | 1/11 |
| DehydrationMetabolism and nutrition disorders | 1/4 | 0/7 | 1/11 |
| Device breakageProduct Issues | 1/4 | 0/7 | 1/11 |
| Device occlusionProduct Issues | 1/4 | 0/7 | 1/11 |
| EpilepsyNervous system disorders | 1/4 | 0/7 | 1/11 |
| Hepatic failureHepatobiliary disorders | 1/4 | 0/7 | 1/11 |
| Metabolic acidosisMetabolism and nutrition disorders | 1/4 | 0/7 | 1/11 |
| PyrexiaGeneral disorders | 1/4 | 0/7 | 1/11 |
| SepsisInfections and infestations | 1/4 | 0/7 | 1/11 |
| Event | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total Participants |
|---|---|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 2/4 | 1/7 | 3/11 |
| NasopharyngitisInfections and infestations | 2/4 | 3/7 | 5/11 |
| InfluenzaInfections and infestations | 1/4 | 3/7 | 4/11 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 2/7 | 2/11 |
| EczemaSkin and subcutaneous tissue disorders | 0/4 | 2/7 | 2/11 |
| EnterocolitisGastrointestinal disorders | 0/4 | 2/7 | 2/11 |
| Abdominal distensionGastrointestinal disorders | 1/4 | 0/7 | 1/11 |
| Anal abscessInfections and infestations | 1/4 | 1/7 | 2/11 |
| Back painMusculoskeletal and connective tissue disorders | 1/4 | 1/7 | 2/11 |
| CellulitisInfections and infestations | 1/4 | 0/7 | 1/11 |
The safety population included all enrolled participants in the study. Data reported in baseline measures was collected at baseline of core studies (SHP633-306 \[NCT03663582\] or TED-C14-004 \[NCT02340819\]).
| Age, Continuous(years) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| Mean | 40.8 ± 12.28 | 42.4 ± 7.21 | 41.8 ± 8.78 |
| Sex: Female, Male(Participants) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 2 | 5 | 7 |
| Ethnicity (NIH/OMB)(Participants) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 4 | 7 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 7 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| Japan | 4 | 7 | 11 |
| Height(centimeter (cm)) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| Mean | 161.10 ± 6.168 | 167.77 ± 6.735 | 165.35 ± 7.068 |
| Weight(kilogram (kg)) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| Mean | 49.29 ± 10.010 | 56.01 ± 10.958 | 53.57 ± 10.660 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | SHP633-306: Teduglutide 0.05 mg/kg | TED-C14-004: Teduglutide 0.05 mg/kg | Total |
|---|---|---|---|
| Mean | 18.96 ± 3.441 | 19.80 ± 3.153 | 19.49 ± 3.114 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).
Ran from Jul 2018 to primary completion in Jan 2022, 42 months.
Results were first posted in Mar 2023, 1 year 2 months after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 42 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide